Rosuvastatin & Amlodipine Interaction

Rosuvastatin and amlodipine are frequently co-prescribed in patients with hypertension and dyslipidemia, two major cardiovascular risk factors that commonly coexist ^[1][2]. The interaction between these drugs is minor — there is no clinically significant pharmacokinetic or pharmacodynamic interaction, and the combination is considered safe and therapeutically beneficial ^[1][2][3].

Unlike simvastatin, which has a major interaction with amlodipine due to CYP3A4 competition (FDA limits simvastatin to 20 mg with amlodipine), rosuvastatin is minimally metabolized by CYP enzymes ^[1][3]. Rosuvastatin is primarily eliminated through hepatic uptake (via OATP1B1 and OATP1B3 transporters) and biliary/renal excretion, with less than 10% undergoing CYP2C9 metabolism ^[1]. Amlodipine is metabolized by CYP3A4 but does not inhibit the transport or metabolism pathways relevant to rosuvastatin ^[2].

Fixed-dose combination products containing rosuvastatin and amlodipine (e.g., Caduet uses atorvastatin, but rosuvastatin-amlodipine combinations exist internationally) highlight the recognized therapeutic value and safety of co-prescribing these drugs ^[3].

Rosuvastatin is a hydrophilic statin that differs from lipophilic statins (simvastatin, atorvastatin, lovastatin) in its minimal CYP450 metabolism ^[1]. It is actively transported into hepatocytes by OATP1B1 and OATP1B3, where it inhibits HMG-CoA reductase. Approximately 90% of rosuvastatin elimination occurs through biliary excretion and renal clearance, with less than 10% metabolized by CYP2C9 ^[1].

Amlodipine is metabolized extensively by CYP3A4 to inactive pyridine metabolites ^[2]. Importantly, amlodipine does not meaningfully inhibit or induce CYP2C9, OATP1B1, or OATP1B3 — the pathways relevant to rosuvastatin disposition ^[2][3]. Similarly, rosuvastatin does not affect CYP3A4, the pathway relevant to amlodipine metabolism.

The absence of shared metabolic pathways explains why no pharmacokinetic interaction has been observed in clinical studies. The pharmacodynamic effects are complementary: rosuvastatin reduces LDL cholesterol and cardiovascular events, while amlodipine reduces blood pressure and provides anti-anginal effects ^[1][2][3].

The clinical significance is minor and predominantly positive ^[1][2][3]. There are no adverse pharmacokinetic or pharmacodynamic interactions. The primary clinical note is that rosuvastatin is a preferred statin choice when a patient requires amlodipine, specifically because it avoids the CYP3A4-mediated interaction that limits simvastatin dosing with amlodipine ^[3].

The ASCOT-LLA trial demonstrated that adding atorvastatin to amlodipine-based antihypertensive therapy reduced cardiovascular events by 36%, supporting the broader principle of combined lipid-lowering and blood pressure treatment ^[3]. While this trial used atorvastatin, the cardiovascular benefit extends to rosuvastatin, which has its own robust outcomes evidence (JUPITER trial).

No dose adjustments are needed for either drug when used in combination ^[1][2]. Standard dosing applies: rosuvastatin 5-40 mg daily based on LDL target, and amlodipine 2.5-10 mg daily for blood pressure control. Both drugs can be taken at any time of day and at the same time for patient convenience. There is no need for special monitoring beyond standard care for each drug independently ^[1][2][3].

Standard lipid monitoring: fasting lipid panel at baseline, 4-12 weeks after starting or adjusting rosuvastatin, then every 6-12 months ^[1]. Liver function tests if clinically indicated (routine monitoring no longer recommended per 2018 ACC/AHA guidelines unless symptoms develop). Blood pressure monitoring per standard hypertension guidelines. Report unexplained muscle pain, tenderness, or weakness (statin myopathy screening) — though rosuvastatin-amlodipine does not increase myopathy risk above rosuvastatin alone ^[1][3].

If rosuvastatin is not tolerated: pravastatin is another hydrophilic statin with minimal CYP metabolism, making it equally safe with amlodipine. Atorvastatin is metabolized by CYP3A4 but has no clinically significant interaction with amlodipine at standard doses (unlike simvastatin). If amlodipine is not tolerated: nifedipine, felodipine, or other dihydropyridine CCBs have similar statin interaction profiles. Non-dihydropyridine CCBs (diltiazem, verapamil) are strong CYP3A4 inhibitors and do interact significantly with lipophilic statins ^[3].